SparX Biopharmaceutical

Ownership

Private

Employees

~100

Therapeutic Areas

Oncology

Stage

Phase 1

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

AntibodiesBispecific antibodiesAntibody-drug conjugates (ADCs)Multi-specific antibodies

SparX Biopharmaceutical General Information

First patient dosed with SPX-303 (anti-LILRB2/PD-L1 bispecific antibody) in April 2024. FDA approved IND application for SPX-303 in October 2023.

Contact Information

Website

https://www.linkedin.com/company/sparx-biopharmaceutical

Primary Industry

Biotech

Corporate Office

Mount Prospect, Illinois
United States

Drug Pipeline

SPX-303

Phase 1

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to SparX Biopharmaceutical's pipeline data

Key Partnerships

Arovella Therapeutics (for CLDN18.2-CAR-iNK development)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

SparX Biopharmaceutical Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view SparX Biopharmaceutical's complete valuation and funding history, request access »

SparX Biopharmaceutical Financial Metrics